Pages that link to "Q35130149"
Jump to navigation
Jump to search
The following pages link to In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. (Q35130149):
Displaying 6 items.
- Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults (Q33487556) (← links)
- Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically ac (Q33977786) (← links)
- Novel Cost-Effective Approaches to the Treatment of Community-Acquired Infections (Q41707304) (← links)
- Prevalence and clinical significance of community‐acquired penicillin‐resistant pneumococcal pneumonia in Thailand (Q44445312) (← links)
- Efficacy of vancomycin plus levofloxacin combination therapy for refractory pericarditis due to multiresistant Streptococcus pneumoniae (Q44680484) (← links)
- Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract (Q77428146) (← links)